Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation (Q38003114)

26 August 2017

Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation (English)

1 reference

26 August 2017

Eberhard Standl

1

1 reference

PubMed ID

22508699

26 August 2017

Oliver Schnell

series ordinal

2

1 reference

PubMed ID

22508699

26 August 2017

language of work or name

English

0 references

publication date

16 April 2012

1 reference

Diabetes and Vascular Disease Research

26 August 2017

1 reference

26 August 2017

9

1 reference

26 August 2017

163-169

1 reference

26 August 2017

3

1 reference

Effects of intensive glucose lowering in type 2 diabetes

26 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Effects of intensive blood-pressure control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Acarbose: oral anti-diabetes drug with additional cardiovascular benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Postprandial hyperglycemia and glycemic variability: should we care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Excess glycaemic excursions after an oral glucose tolerance test compared with a mixed meal challenge and self-measured home glucose profiles: is the OGTT a valid predictor of postprandial hyperglycaemia and vice versa?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Effects of acarbose on the acceleration of postprandial hyperglycemia-induced pathological changes induced by intermittent hypoxia in lean mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Effect of nateglinide on the incidence of diabetes and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441524

21 January 2018

Identifiers

DOI

10.1177/1479164112441524

1 reference

26 August 2017

1 reference

PubMed ID

22508699